Extraskeletal Myxoid Chondrosarcoma

The name is somewhat misleading, and that is the first point I would make: despite being called a chondrosarcoma, extraskeletal myxoid chondrosarcoma does not show true cartilage differentiation. It is a distinct, rare soft-tissue sarcoma of uncertain differentiation, defined molecularly by NR4A3 gene rearrangement, most commonly the EWSR1-NR4A3 fusion, with some variant fusion partners. It typically arises as a deep mass of the proximal limbs or limb girdles, especially the thigh, in adults, and histologically shows a myxoid matrix with a multilobular architecture and cords or clusters of relatively uniform eosinophilic ovoid-to-short-spindle cells, so the molecular NR4A3 finding is valuable for confirming the diagnosis, particularly given the morphological and fusion variants. Clinically, its behaviour is distinctive and important for management: it is generally indolent but relapsing over the long term, with a propensity for local recurrence and late metastases, often to the lung, sometimes years after treatment. So I would manage it as a soft-tissue sarcoma at a specialist sarcoma centre: MRI of the primary, a properly planned biopsy with molecular confirmation of NR4A3 rearrangement, and wide surgical resection with clear margins as the mainstay, since it is relatively resistant to chemotherapy and radiotherapy, which therefore have only a limited, selective role. Crucially, because of the late relapse pattern, I would arrange prolonged surveillance including chest imaging rather than being reassured by a good short-term result, and I would avoid any unplanned excision of the undiagnosed mass.